日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Pelabresib联合ruxolitinib治疗JAK抑制剂初治骨髓纤维化:一项随机3期试验

Rampal, Raajit K; Grosicki, Sebastian; Chraniuk, Dominik; Abruzzese, Elisabetta; Bose, Prithviraj; Gerds, Aaron T; Vannucchi, Alessandro M; Palandri, Francesca; Lee, Sung-Eun; Gupta, Vikas; Lucchesi, Alessandro; Oh, Stephen T; Kuykendall, Andrew T; Patriarca, Andrea; Álvarez-Larrán, Alberto; Mesa, Ruben; Kiladjian, Jean-Jacques; Talpaz, Moshe; Scandura, Joseph M; Lavie, David; Harris, Morgan; Kays, Sarah-Katharina; Li, Qing; Boxhammer, Rainer; Brown, Barbara; Jegg, Anna-Maria; Harrison, Claire N; Mascarenhas, John

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

一项评估 Felzartamab 治疗抗磷脂酶 A2 受体自身抗体阳性原发性膜性肾病安全性和有效性的 1b/2a 期研究

Rovin, Brad H; Ronco, Pierre M; Wetzels, Jack F M; Adler, Sharon G; Ayoub, Isabelle; Zaoui, Philippe; Han, Seung Hyeok; Dudani, Jaideep S; Gilbert, Houston N; Patel, Uptal D; Manser, Paul T; Jauch-Lembach, Julia; Faulhaber, Nicola; Boxhammer, Rainer; Härtle, Stefan; Sprangers, Ben

Immunologic Responses After COVID-19 Vaccination in Patients With Membranous Nephropathy Receiving Anti-CD38 Felzartamab Therapy: Results From the Phase 1b/2a M-PLACE Study

接受抗CD38 Felzartamab治疗的膜性肾病患者接种COVID-19疫苗后的免疫反应:来自1b/2a期M-PLACE研究的结果

Rovin, Brad H; Boxhammer, Rainer; Thakur, Anjali; Ronco, Pierre M

Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.

Tafasitab 与 α1T 细胞或同种异体 NK 细胞疗法联合使用,可杀伤 B 细胞非霍奇金淋巴瘤

Her Jung Hyun, Pretscher Dominik, Patra-Kneuer Maria, Schanzer Juergen, Cho Sung Yoo, Hwang Yu Kyeong, Hoeres Timm, Boxhammer Rainer, Heitmueller Christina, Wilhelm Martin, Steidl Stefan, Endell Jan

Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial

单克隆CD38抗体felzartamab治疗晚期抗体介导的肾移植排斥反应的安全性、耐受性和有效性:一项II期试验的研究方案

Mayer, Katharina A; Budde, Klemens; Halloran, Philip F; Doberer, Konstantin; Rostaing, Lionel; Eskandary, Farsad; Christamentl, Anna; Wahrmann, Markus; Regele, Heinz; Schranz, Sabine; Ely, Sarah; Firbas, Christa; Schörgenhofer, Christian; Kainz, Alexander; Loupy, Alexandre; Härtle, Stefan; Boxhammer, Rainer; Jilma, Bernd; Böhmig, Georg A

α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

使用²¹³Bi-抗CD38免疫偶联物的α放射免疫疗法在人类多发性骨髓瘤小鼠模型中有效。

Teiluf, Katharina; Seidl, Christof; Blechert, Birgit; Gaertner, Florian C; Gilbertz, Klaus-Peter; Fernandez, Vanesa; Bassermann, Florian; Endell, Jan; Boxhammer, Rainer; Leclair, Stephane; Vallon, Mario; Aichler, Michaela; Feuchtinger, Annette; Bruchertseifer, Frank; Morgenstern, Alfred; Essler, Markus